Jules Musing, Former Senior Executive at Johnson & Johnson, Joins Variant Pharmaceuticals' Board of Directors

WESTON, Fla., Oct. 20, 2016 /PRNewswire/ -- Variant Pharmaceuticals, Inc., an emerging specialty pharmaceutical company developing first-in-class drugs for patients with rare diseases, announced today that its Board of Directors has appointed Jules Musing, former Senior Executive at Johnson & Johnson, as a Director of the Board.

Mr. Musing, in the course of his 36-year career, has been responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products, as well as creation of strategic alliances and partnerships on a global basis. Under his leadership, numerous multi-million dollar deals were executed with pharmaceutical and biotechnology companies worldwide. He has been President of Johnson & Johnson companies in the US and Europe, and he was on the Board of Johnson & Johnson companies in Germany, France, Italy, and the UK. Mr. Musing has been a member of the Management Board of Ortho Biotech (a J&J Biotechnology Company) in the US and Europe, CEO and President of Ares Serono, Inc. in the US, and Executive Vice President with responsibilities for Ares Serono companies in North and Latin America.

"Along with his knowledge of and passion for creating global pharmaceutical and biotechnology strategic alliances and partnerships, and brokering deals," said Stephen Glover, Founder and CEO of Variant Pharmaceuticals, "Jules Musing will bring to our Board his unique expertise to help optimize the value of our rare disease product portfolio". 

About Variant

Variant Pharmaceuticals, an emerging pharmaceutical company focusing on restoring health and transforming the lives of patients with rare diseases through innovation, was established in 2014, with the mission to become a leading specialty pharmaceutical company.  Our evolving product pipeline is targeted to the $100+ billion orphan drug market. Our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (HPβCD) for chronic treatment of two orphan indications, VAR 200: Focal Segmental Glomerulosclerosis (FSGS) and VAR 300: Alport Syndrome (AS), rare progressive forms of kidney disease.   

Logo - http://photos.prnewswire.com/prnh/20151217/297056LOGO

SOURCE Variant Pharmaceuticals, Inc.